Quick Answer
Moderna, Inc. reported Stockholders Equity of $8.65 billion for the year ending 2025.
- Moderna, Inc. showed a decrease of -20.6% in Stockholders Equity from 2024 to 2025.
- This data is from Moderna, Inc.'s annual report (Form 10-K), filed with the SEC on February 20, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$613.71 million | Q2 2018: -$688.77 million | Q3 2018: -$757.13 million | Q1 2019: $1.44 billion | Q2 2019: $1.33 billion | Q3 2019: $1.25 billion | Q1 2020: $1.64 billion | Q2 2020: $2.95 billion | Q3 2020: $2.76 billion | Q1 2021: $3.84 billion | Q2 2021: $6.70 billion | Q3 2021: $10.12 billion | Q1 2022: $17.08 billion | Q2 2022: $17.99 billion | Q3 2022: $17.99 billion | Q1 2023: $18.86 billion | Q2 2023: $16.95 billion | Q3 2023: $13.46 billion | Q1 2024: $12.82 billion | Q2 2024: $11.71 billion | Q3 2024: $11.93 billion | Q1 2025: $10.07 billion | Q2 2025: $9.40 billion | Q3 2025: $9.33 billion.
- Over the full 11 years of available data (2015 to 2025), Moderna, Inc.'s Stockholders Equity has grown by 5,875.9%.
- Historical annual values: Fiscal year 2025: $8.65 billion | Fiscal year 2024: $10.90 billion | Fiscal year 2023: $13.85 billion | Fiscal year 2022: $19.12 billion | Fiscal year 2021: $14.15 billion | Fiscal year 2020: $2.56 billion | Fiscal year 2019: $1.18 billion | Fiscal year 2018: $1.53 billion | Fiscal year 2017: -$551.37 million | Fiscal year 2016: -$334.81 million | Fiscal year 2015: -$149.76 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: